Thursday, July 23, 2015

SutroVax Finds $22M

South San Francisco-based SutroVax, a biopharmaceuticals startup that is developing vaccines for infection disease targets, said this morning that it has raised $22M in a Series A funding. The funding was led by Abingworth, and also included Longitude Capital, Roche Venture Fund and CTI Life Sciences Fund. The company--which is a spinout of Sutro Biopharma--said it has a license from Sutro Biopharma for its technology. More information »